---
document_datetime: 2023-09-21 18:05:43
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-sandoz-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-sandoz-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.532358
conversion_datetime: 2025-12-27 22:51:46.455651
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Clopidogrel Sandoz

Procedural steps taken and scientific information after the authorisation

| No        | Scope                                                                                                                                                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| WS/0052   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To add a new active substance manufacturer. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the active substance that is supported by an ASMF | 18/11/2010                          | 06/12/2010                                  |                                  |           |
| WS/0053/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                | 21/10/2010                          | 05/11/2010                                  |                                  |           |

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400 Facsimile +44 (0) 20 7523 7455

E-mail

info@ema.europa.eu Website www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
|         | Harmonization of the active substance and finished product specifications of the genotoxic impurities between AS manufacturers and FP manufacturer. Additionally the analytical method used for the determination of genotoxic impurities has been changed. B.I.b.2.e - Change in test procedure for active substance or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate, B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the active substance, B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits, B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range, B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or |                                     |                                             |                                  |           |
| IB/0010 | C.I.2.a - Change in the SPC, Labelling or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 06/08/2010                          | n/a                                         | SPC, Labelling,                  |           |

<div style=\"page-break-after: always\"></div>

| No       | Scope                                                                                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                               |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------|
|          | PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                  |                                     |                                             | PL                               |                                                                                                       |
| N/0009   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                      | 03/06/2010                          | n/a                                         | PL                               |                                                                                                       |
| IA/0008  | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                    | 12/04/2010                          | n/a                                         |                                  |                                                                                                       |
| A20/0007 | Pursuant to Article 20 of Regulation (EC) No 726/2004 of 31 March 2004, the European Commission requested on 18 March 2010, the opinion of the CHMP on measures necessary to ensure the quality of the above mentioned medicinal product further to GMP deficiencies of the API manufacturing site Glochem Industries Ltd. (Unit II). | 18/03/2010                          | 16/09/2010                                  |                                  | Please refer to the Assessment Report: Clopidogrel Sandoz-H-1174-A20-07- Assessment Report-Article 20 |
| II/0004  | To introduce a new active substance manufacturer. Quality changes                                                                                                                                                                                                                                                                     | 20/01/2010                          | 09/02/2010                                  |                                  |                                                                                                       |
| II/0005  | To register a revised version of the ASMF for clopidogrel besilate from the existing active substance manufacturer, introducing changes in the manufacturing process of the active substance. Quality changes                                                                                                                         | 20/01/2010                          | 09/02/2010                                  |                                  |                                                                                                       |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0006 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                          | 27/01/2010                          | n/a                                         |                                  |           |
| IA/0001 | 07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms, 07_a_Replacement/add. of manufacturing site: Secondary packaging site | 14/10/2009                          | n/a                                         |                                  |           |
| IA/0002 | 07_a_Replacement/add. of manufacturing site: Secondary packaging site, 07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms | 14/10/2009                          | n/a                                         |                                  |           |
| IA/0003 | 08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                               | 13/10/2009                          | n/a                                         | Annex II, PL                     |           |